Senna and the formation of aberrant crypt foci and tumors in rats treated with azoxymethane

Phytomedicine

Volumn 12, Issue 6-7, 2005, Pages 501-505

  Borrelli, F ^a   Capasso, R ^a   Aviello, G ^a   Di Carlo, G ^a   Izzo, A A ^a   Mascolo, N ^a   Capasso, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aberrant crypt foci; Anthraquinones; Laxative; Senna; Tumors

Indexed keywords

ANTINEOPLASTIC AGENT; AZOXYMETHANE; CARCINOGEN; SENNA EXTRACT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CHRONIC DRUG ADMINISTRATION; COLON CANCER; COLON CARCINOGENESIS; CONSTIPATION; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SENNA; STATISTICAL SIGNIFICANCE;

ANIMALIA; SENNA;

EID: 19944373403     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2003.10.008     Document Type: Article

References (29)

1. Borrelli, F., Mereto, E., Capasso, F., Orsi, P., Sini, D., Izzo, A.A., Massa, B., Boggio, M., Mascolo, N., 2001. Effect of bisacodyl and cascara on growth of aberrant crypt foci and malignant tumors in the rat colon. Life Sci. 69, 1871-1877.
2. Brown, J.P., 1980. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat. Res. 75, 243-277.
3. Brown, J.P., Brown, R.J., 1976. Mutagenesis by 9,10-anthraquinone derivatives and related compounds in Salmonella typhimurium. Mutat. Res. 40, 203-224.
4. Brusick, D., Mengs, U., 1997. Assessment of the genotoxic risk from laxative senna products. Environ. Mol. Mutagen. 29, 1-19.
5. Capasso, F., Gaginella, T.S., 1997. Laxative. A Practical Guide. Springer-verlag Italia, Milan.
6. Gardiner, J.S., Walker, S.A., MacLean, A.J., 1982. A retrospective mortality study of substituted anthraquinone dyestuffs workers. Br. J. Ind. Med. 39, 355-360.
7. Gattuso, J.M., Kamm, M.A., 1994. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf. 10, 47-65.
8. Jacobs, E.J., White, E., 1998. Constipation, laxative use and colon cancer among middle-aged adults. Epidemiology 9, 385-391.
9. Kune, G.A., Kune, S., Field, B., Watson, L.F., 1988. The role of chronic constipation, diarrhea, and laxative use in the etiology of large-bowel cancer. Data from the Melbourne Colorectal Cancer Study. Dis. Colon Rectum 31, 507-512.
10. Leng-Peschlow, E., 1992. Senna: its rational uses. Pharmacology 44, 1-52.
11. Leng-Peschlow, E., Odenthal, K.P., Voderholzer, W., Muller-Lissner, S., 1993. Chronic sennoside treatment does not cause habituation and secondary hyperaldosteronism in rats. Pharmacology 47, 162-171.
12. Lyden-Sokolowski, A., Nilsson, A., Sjoberg, P., 1993. Twoyear carcinogenicity study with sennosides in the rat: emphasis on gastro-intestinal alterations. Pharmacology 47, 209-215.
13. Mascolo, N., Mereto, E., Borrelli, F., Orsi, P., Sini, D., Izzo, A.A., Massa, B., Boggio, M., Capasso, F., 1999. Does senna extract promote growth of aberrant crypt foci and malignant tumors in rat colon? Dig. Dis. Sci. 44, 2226-2230.
14. McLellan, E.A., Medline, A., Bird, R.P., 1991. Sequential analyses of the growth and morphogical characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res. 51, 5270-5274.
15. Mengs, U., 1988. Toxic effects of sennosides in laboratory animals and in vitro. Pharmacology 36, 180-187.
16. Mori, H., Sugie, S., Niwa, K., Takahashi, M., Kawai, K., 1985. Induction of intestinal tumors in rats by chrysazin. Br. J. Cancer 52, 781-783.
17. Mori, H., Mori, Y., Tanaka, T., Yoshimi, N., Sugie, S., Kawamori, T., Narisawa, T., 1992. Cell kinetic analysis of the mucosal epithelium and assay of ornithine decarboxylase activity during the process of 1-hydroxyanthraquinone- induced large bowel carcinogenesis in rats. Carcinogenesis 13, 2217-2220.
18. Morimoto, I., Watanabe, F., Osawa, T., Okitsu, T., Kada, T., 1982. Mutagenicity screening of crude drugs with Bacillus subtilis rec-assay and Salmonella/microsome reversion assay. Mutat. Res. 97, 81-102.
19. Muller Lissner, S.A., 1993. Adverse effects of laxative fact and action. Pharmacology 47, 138-145.
20. Nakamura, G.J., Schneiderman, L.J., Klauber, M.R., 1984. Colorectal cancer and bowel habits. Cancer 54, 1475-1477.
21. Nascimbeni, R., Donato, F., Ghirardi, M., Mariani, P., Villanacci, V., Salerni, B., 2002. Constipation, anthranoid laxatives, melanosis coli, and colon cancer: a risk assessment using aberrant crypt foci. Cancer Epidemiol. Biomarkers Prev. 11, 753-757.
22. Roberts, M.C., Millikan, R.C., Galanko, J.A., Martin, C., Sandler, R.S., 2003. Constipation, laxative use, and colon cancer in a North Carolina population. Am. J. Gastroenterol. 98, 857-864.
23. Sandnes, D., Johansen, T., Teinen, G., Ulsaker, G., 1992. Mutagenicity of crude senna and senna glycosides in Salmonella typhimurium. Pharmacol. Toxicol. 71, 165-172.
24. Schiller, L.R., 2001. Review article: the therapy of constipation. Aliment. Pharmacol. Ther. 15, 749-763.
25. Siegers, C.P., Siemers, J., Baretton, G., 1993a. Sennosides and aloin do not promote dimethylhydrazine-induced colorectal tumors in mice. Pharmacology 47 (suppl 1), 205-208.
26. Siegers, C.P., Von Hertzberg-Lottin, E., Otte, M., Schneider, B., 1993b. Antranoid laxative abuse - a risk for colorectal cancer? Gut 34, 1099-1101.
27. Thorpe, D.M., 2001. Management of opioid-induced constipation. Curr. Pain Headache Rep. 5, 237-240.
28. Westendorf, J., Marquardt, H., Poginsky, B., Dominiak, M., Schimdt, J., Marquardt, H., 1990. Genotoxicity of naturally occurring hydroxyantraquinones. Mutat. Res. 240, 1-12.
29. Xing, J.H., Soffer, E.E., 2001. Adverse effects of laxatives. Dis. Colon Rectum 44, 1201-1209.